Enzyme inhibitors

Global Kinase Inhibitors Market Report 2021: Data from 2019, 2020 Estimates for 2021 and Projections of CAGRs Through 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Pharmaceutical, Health, Protein kinase inhibitors, Lactams, Tyrosine kinase inhibitors, Drugs, Morpholines, Enzyme inhibitors

The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.

Key Points: 
  • The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.
  • This report is designed to be a business tool that will provide a thorough evaluation of the markets for kinase inhibitors.
  • Various types of kinase inhibitors have been analyzed in the report, and along with their different application scenarios, the scope of this study includes regulatory aspects, pipeline analysis and demand for kinase inhibitors.
  • The market for kinase inhibitor market is experiencing an increasing demand for a number of novel kinase inhibitors being utilized in human trials.

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 17, 2021
Enzymes, Aldosterone synthase, ROCK2, Forward-looking statement, Kinase, Tyrosine kinase, Enzyme inhibitors

Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.

Key Points: 
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
  • Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.\nThree Months Ended March 31,\n'

RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 24, 2021
Enzyme inhibitors, Antineoplastic drugs, Protein kinase inhibitors, Clinical medicine, RET inhibitor, Medicine, Targeted therapy, Drugs, Immune system

NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:
    Global RET Inhibitors Market Opportunity: > USD 1.5 Billion
    RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase
    RET Inhibitors In Clinical Trials: > 15 Drugs
    First RET Inhibitor Approved In 2020: Retevmo
    High spaced cancer cases across the globe are leading to the development of several novel and specific targeted therapies like RET inhibitor therapy which has emerged as innovative therapeutic approach.
  • RET inhibitor drug market is highly classified as one of the top and most promising therapeutics sectors in the total cancer therapeutics market.
  • It is believed that in the future years, the entire healthcare applications associated with RET inhibitors, i.e.
  • As per "Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" report findings, it is observed that the market holds the capacity to deliver unrealistic healthcare benefits, inclining the entire therapy to attain a market size and growth rate that is higher than any other cancer therapy.

RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 24, 2021
Enzyme inhibitors, Antineoplastic drugs, Protein kinase inhibitors, Clinical medicine, RET inhibitor, Medicine, Targeted therapy, Drugs, Immune system

NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:
    Global RET Inhibitors Market Opportunity: > USD 1.5 Billion
    RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase
    RET Inhibitors In Clinical Trials: > 15 Drugs
    First RET Inhibitor Approved In 2020: Retevmo
    High spaced cancer cases across the globe are leading to the development of several novel and specific targeted therapies like RET inhibitor therapy which has emerged as innovative therapeutic approach.
  • RET inhibitor drug market is highly classified as one of the top and most promising therapeutics sectors in the total cancer therapeutics market.
  • It is believed that in the future years, the entire healthcare applications associated with RET inhibitors, i.e.
  • As per "Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" report findings, it is observed that the market holds the capacity to deliver unrealistic healthcare benefits, inclining the entire therapy to attain a market size and growth rate that is higher than any other cancer therapy.

2020 Beta Secretase Inhibitor Pipeline Insight - ResearchAndMarkets.com

Retrieved on: 
Friday, August 7, 2020
Pharmaceutical, Health, Clinical trials, Integral membrane proteins, Alzheimer's disease, Branches of biology, Proteins, Molecular biology, Molecular neuroscience, Beta-secretase 1, Enzyme inhibitors, Amyloid precursor protein secretase

The "Beta Secretase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Beta Secretase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Beta Secretase Inhibitor pipeline landscape is provided, which includes the topic overview and Beta Secretase Inhibitor mechanism of action.
  • The assessment part of the report embraces, in-depth Beta Secretase Inhibitor commercial assessment and clinical assessment of the pipeline products under development.
  • Elucidated Beta Secretase Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.

2020 Pipeline Insight for Gamma Secretase Inhibitors - ResearchAndMarkets.com

Retrieved on: 
Friday, August 7, 2020
Other Manufacturing, Manufacturing, Proteins, Integral membrane proteins, Branches of biology, Alzheimer's disease, Gamma secretase, Amyloid precursor protein secretase, Enzyme inhibitors

The "Gamma Secretase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gamma Secretase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Gamma Secretase Inhibitor pipeline landscape is provided, which includes the topic overview and Gamma Secretase Inhibitor mechanism of action.
  • The assessment part of the report embraces, in-depth Gamma Secretase Inhibitor commercial assessment and clinical assessment of the pipeline products under development.
  • Elucidated Gamma Secretase Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.

Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 27, 2019
Health, Oncology, Pharmaceutical, Cannabinoids, Chemical compounds, Chemistry, Drugs, Enzyme inhibitors, Fatty acid amide hydrolase, Endocannabinoids, Carbamates, Endocannabinoid enhancer, MK-4409

The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine